公开(公告)号：US09642904B2

公开(公告)日：2017-05-09

申请号：US14961772

申请日：2015-12-07

Applicant: GlaxoSmithKline Biologicals SA

Inventor： Fabio Bagnoli ,  Massimiliano Biagini ,  Luigi Fiaschi ,  Guido Grandi ,  Ravi Pratap Narayan Mishra ,  Nathalie Norais ,  Maria Scarselli

IPC: A61K39/085 ,  C07K14/31 ,  A61K39/00

CPC classification number: A61K39/085 ,  A61K39/00 ,  C07K14/31 ,  C07K2319/00

Abstract: An effective Staphylococcus aureus vaccine may require several antigenic components, and so various combinations of S. aureus antigens are identified for use in immunisation. These polypeptides may optionally be used in combination with S. aureus saccharides.

公开(公告)号：US10035826B2

公开(公告)日：2018-07-31

申请号：US15150204

申请日：2016-05-09

Applicant: GlaxoSmithKline Biologicals SA ,  J. Craig Venter Institute, Inc.

Inventor： Vega Masignani ,  Danilo Gomes Moriel ,  Francesco Berlanda Scorza ,  Nathalie Norais ,  Maria Rita Fontana ,  Mariagrazia Pizza ,  Laura Serino ,  Herve Tettelin

IPC: A61K39/02 ,  C07K14/245 ,  C07K16/12 ,  A61K39/108 ,  A61K39/00

CPC classification number: C07K14/245 ,  A61K39/00 ,  A61K39/0258 ,  A61K2039/505 ,  A61K2039/523 ,  C07K16/1232

Abstract: Disclosed herein are various open reading frames from a strain of E. coli responsible for neonatal meningitis (MNEC), and a subset of these that is of particular interest for preparing compositions for immunizing against MNEC infections.

公开(公告)号：US09771399B2

公开(公告)日：2017-09-26

申请号：US14927052

申请日：2015-10-29

Applicant: GlaxoSmithKline Biologicals SA

Inventor： Jeannette Adu-Bobie ,  Mariagrazia Pizza ,  Nathalie Norais ,  Germano Ferrari ,  Guido Grandi

IPC: C07K14/22 ,  A61K39/095 ,  C07K14/245 ,  C12N9/10 ,  A61K39/108 ,  A61K39/00

CPC classification number: C07K14/245 ,  A61K39/00 ,  A61K39/0258 ,  A61K39/095 ,  C07K14/22 ,  C12N9/1051 ,  Y02A50/474

Abstract: Knockout of the meningococcal mltA homolog gives bacteria that spontaneously release vesicles that are rich in immunogenic outer membrane proteins and that can elicit cross-protective antibody responses with higher bactericidal titers than OMVs prepared by normal production processes. Thus the invention provides a bacterium having a knockout mutation of its mltA gene. The invention also provides a bacterium, wherein the bacterium: (i) has a cell wall that includes peptidoglycan; and (ii) does not express a protein having the lytic transglycosylase activity MltA protein. The invention also provides compositions comprising vesicles that, during culture of bacteria of the invention, are released into the culture medium.

公开(公告)号：US10336794B2

公开(公告)日：2019-07-02

申请号：US15698434

申请日：2017-09-07

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Jeannette Adu-Bobie ,  Mariagrazia Pizza ,  Nathalie Norais ,  Germano Ferrari ,  Guido Grandi

IPC: A61K39/02 ,  C07K14/22 ,  C07K14/245 ,  A61K39/095 ,  C12N9/10 ,  A61K39/108 ,  A61K39/00

Abstract: Knockout of the meningococcal mltA homolog gives bacteria that spontaneously release vesicles that are rich in immunogenic outer membrane proteins and that can elicit cross-protective antibody responses with higher bactericidal titres than OMVs prepared by normal production processes. Thus the invention provides a bacterium having a knockout mutation of its mltA gene. The invention also provides a bacterium, wherein the bacterium: (i) has a cell wall that includes peptidoglycan; and (ii) does not express a protein having the lytic transglycosylase activity MltA protein. The invention also provides compositions comprising vesicles that, during culture of bacteria of the invention, are released into the culture medium.

公开(公告)号：US10279026B2

公开(公告)日：2019-05-07

申请号：US14396881

申请日：2013-04-24

Applicant: GlaxoSmithKline Biologicals SA

Inventor： Marco Soriani ,  Maria Scarselli ,  Nathalie Norais ,  Danilo Gomes Moriel ,  Silvia Rossi Paccani

IPC: A61K39/102 ,  A61K39/095 ,  C07K14/285 ,  A61K39/02 ,  C12R1/21 ,  A61K39/00

Abstract: NTHI protein antigens have been identified and found to be conserved across several Haemophilus influenzae pathogenic strains. They have been isolated, cloned from a reference strain and tested for immunogenicity. Methods for immunization and vaccines derived thereof are also disclosed.

公开(公告)号：US10195263B2

公开(公告)日：2019-02-05

申请号：US15589834

申请日：2017-05-08

Applicant: GlaxoSmithKline Biologicals SA

Inventor： Fabio Bagnoli ,  Massimiliano Biagini ,  Luigi Fiaschi ,  Guido Grandi ,  Ravi Pratap Narayan Mishra ,  Nathalie Norais ,  Maria Scarselli

IPC: A61K39/085 ,  C07K14/31 ,  A61K39/00

Abstract: An effective Staphylococcus aureus vaccine may require several antigenic components, and so various combinations of S. aureus antigens are identified for use in immunisation. These polypeptides may optionally be used in combination with S. aureus saccharides.